$7900 | Single User
$20500 | Global License
$25800 | Site License

Chronic Obstructive Pulmonary Disorder (COPD): KOL Insight
[Published by FirstWord Pharma]

Published by FirstWord Pharma: 20 Apr 2015 | 218 | In Stock
Related Topics: Asthma , AstraZeneca , Boehringer Ingelheim , GlaxoSmithKline , Novartis , Pulmonary , Respiratory , Roche

Introduction

Introduction


Combination therapy is set to take centre stage in the treatment of COPD as leading companies such as GlaxoSmithKline (GSK), Boehringer Ingelheim and AstraZeneca vie for market position and share. But will clinicians, payers and patients be persuaded to change from well-established products?


Despite recently approved dual combinations of Long Acting Muscarinic Antagonists (LAMA) and Long Acting Beta2 Agonists (LABA) bringing little novelty to the therapeutic party, companies remained focused on combination approaches. The focus now is on triple combination products, with companies arguing that these will simplify treatment sequencing and provide adherence benefits. But do KOLs agree?


Chronic Obstructive Pulmonary Disorder (COPD): KOL Insight provides answers to this question, plus many more. It includes insight and opinion from 12 leading US and European KOLs, presents business-critical insights for branded pharma and the drug discovery community, and highlights what KOLS think about current treatments, and what new therapies will need to demonstrate for the COPD treatment paradigm to change.


KOL Views Covered


  • LAMAs: Spiriva (Boehringer Ingelheim), Eklira/Tudorzas (AstraZeneca), Seebri (Novartis), Incruse (GSK)

  • LABAs: Arcapta/Onbrez (Novartis), Striverdi (Boehringer Ingelheim)

  • LAMA/LABA combinations: Ultibro (Novartis), Anoro (GSK), Duaklir (AstraZeneca)

  • ICS/LABA combinations, including Seretide/Advair (GSK), Revlar/Breo (GSK), Symbicort (AstraZeneca)

  • Phosphodiesterase-IV inhibitors, including Daliresp/Daxas (Takeda)

  • COPD R&D Pipeline: Triple ICS/LABA/LAMA combinations, ICS/LAMA combinations, Anti-IL5 mAbs, PI3K inhibitors, MAPK inhibitors and MABAs

  • Puchase Reasons


    Key Benefits


  • Know the opinions of KOLs and formulate effective strategies for product positioning and clinician communication

  • Map new treatment options to COPD patients and patient sub-groups

  • Identify product attributes and patient characteristics that the KOLs think are the most important in terms of prescribing decisions

  • Discover which clinical trials the KOLs believe will have a significant impact on future treatment decisions and their likely outcomes

  • Evaluate the changing and challenging competitive landscape

  • Answers to Critical Questions


  • Where next for Boehringer Ingelheim’s blockbuster LAMA Spiriva (tiotropium) when it comes under pressure from combination products?

  • Patient enthusiasm for specific inhaler devices influences prescribing: which are favoured and what are the influences?

  • What positive outcome from the SUMMIT clinical trial could provide a competitive advantage for GSK’s Revlar/Breo combination?

  • How might AstraZeneca exploit positive views of its Genuair/Pressair DPI device for Eklira/Tudorza?

  • Novartis (Ultibro), GSK (Anoro) and AstraZeneca’s Duaklir are locked in battle in the LAMA/LABA sector with Boehringer Ingelheim set to join the fray; but do clinicians see real benefits and what clinical trials could alter perceptions?

  • What are the prospects for developmental anti-IL5 antibodies, MABAs, PI3K inhibitors and MAPK inhibitors and how do clinicians view them?

  • Top Takeaways


  • Know the detailed opinions of leading front line clinicians on current and late stage COPD therapies and what they see as the critical advantages/disadvantages affecting their decision to prescribe

  • Appreciate the important factors affecting the COPD sector and identify key areas for strategic and tactical action

  • Understand how new combination therapies will fit into the treatment paradigm and identify the products that will be adversely affected

  • Review KOL attitudes to important clinical trials such as ATTAIN, ACCORD, GLOW, INVIGORATE, SPARK, ILLUMINATE, FLAME, ACLIFORM, AUGMENT COPD, TONADO 1&2 and SUMMIT

  • Key Opinion Leaders


    North America


  • Dr Nick Gross, Volunteer Attending Physician, St Francis Hospital, Hartford, CT Professor Richard Casaburi, Professor of Medicine and Associate Chief for Research, Division of Respiratory Medicine, Harbor-UCLA Medical Center, Torrance, California

  • Dr Barry Make, Professor of Medicine, Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado School of Medicine, Denver, CO

  • Dr Donald P. Tashkin, Emeritus Professor of Medicine, Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine, University of California Los Angeles

  • Dr Edward Eden, Associate Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons, New York

  • Professor Christopher Cooper, Professor of Medicine and Physiology, David Geffen School of Medicine, University of California, Los Angeles

  • Europe


  • Professor Nicolas Roche, Professor, Respiratory Medicine, Paris Descartes University; Department of Respiratory and Intensive Care Medicine, Cochin-Broca-Hôtel-Dieu Hospital Group; Researcher, Paris Descartes University, France

  • Dr Lipworth, Head, Asthma and Allergy Research Group; Professor, Allergy and Pulmonology at Ninewells Hospital and Medical School, University of Dundee, UK

  • Professor Peter Barnes, Professor of Thoracic Medicine, National Heart and Lung Institute; Head of Respiratory Medicine, Imperial College; Honorary Consultant Physician, Royal Brompton Hospital, London, UK

  • Dr Rene Aalbers, Consultant Physician, Respiratory Medicine at Martini Hospital, Groningen, The Netherlands

  • Anonymous KOL, Germany

  • Anonymous KOL, Germany

  • Update Bulletins Offer Ongoing Benefits


    The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord’s guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.


    Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.


  • Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date, April 2015.

  • You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date
  • Table of Contents
    for Chronic Obstructive Pulmonary Disorder (COPD): KOL Insight [Published by FirstWord Pharma]

    • 1. Executive summary

      2. Research objectives

      3. Research focus

      4.Current market overview

      4.1.Spiriva, Advair/Seretide and Symbicort are the top-selling treatments

      4.2.A disease-modifying therapy is the main unmet need

      4.3.Spirometry is not widely used in clinical practice

      4.4.Earlier detection of COPD is required

      4.5.GOLD’s guideline “quadrant” unsuitable for primary care

      4.6.Inhaled corticosteroids are the most commonly used treatment

      4.7.Patient preference determines device choice

      4.8.Dosing frequency is not critical

      5.Long-Acting Muscarinic Antagonists (LAMAs)

      5.1.Spiriva benefits from a long period of clinical use

      5.2.Eklira/Tudorza’s main advantage is a well-regarded device

      5.3.Seebri’s lower US dosing may not impact efficacy

      5.4.Incruse shares the same device as Anoro and Relvar/Breo

      6.Long-Acting Beta2 Agonists (LABAs)

      6.1.Arcapta/Onbrez has low US formulary coverage

      6.2.Striverdi’s exercise endurance claim rejected by FDA

      7.LAMA/LABA combinations

      7.1.Ultibro FLAME trial results may increase uptake

      7.2.Anoro provides dual bronchodilation below the cost of Spiriva

      7.3.AstraZeneca’s Duaklir and PT003 use different devices

      7.4.Tiotropium/olodaterol results are “underwhelming”

      8.ICS/LABA combinations

      8.1.Seretide/Advair generics now approved in Europe

      8.2.Relvar/Breo adds little clinical value

      8.3.Symbicort late to US market

      9.Phosphodiesterase-IV inhibitors

      9.1.Poor tolerability limits use of Daliresp/Daxas

      10.R&D Pipeline

      10.1.ICS/LABA/LAMA combinations enter Phase III development

      10.2.First ICS/LAMA combination enters development

      10.3.Anti-IL5 antibodies may have a minor role in COPD

      10.4.IL-17 may not be a central mechanism in COPD

      10.5.PI3K inhibitors may reduce COPD progression

      10.6.MAPK inhibitors have safety concerns

      10.7.Further development of MABAs unlikely

      10.8.Inhaled PDE-IV inhibitors may lack efficacy

      10.9.Novel anti-inflammatories and vaccines may reduce exacerbations

      11.Future treatment practice

      11.1.Switching from ICS/LABA to LAMA/LABAs requires ICS withdrawal

      11.2.LAMA/LABA’s main role is in non-exacerbating patients

      11.3.LAMA/LABAs introduce a drug sequencing issue

      11.4.LAMA/LABAs may not be as effective as ICS/LABAs plus LAMA 68Triple combinations are the most convenient treatment option

      11.5.Novel add-on therapy may reduce exacerbations

      11.6.Biomarkers are required to predict treatment response

      12.Appendix

      12.1.COPD market definition

      12.2.US formulary coverage of COPD drugs

      12.3.KOL biographies

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    218 |

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    Global Acute and Chronic Myelogenous Leukemia Partnering 2010 to 2016
    The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
    01 Oct 2016 by Current Partnering USD $1,495 More Info
    Global Chronic Kidney Disease Partnering 2010 to 2016
    The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
    01 Oct 2016 by Current Partnering USD $1,495 More Info
    The Outlook for Wearable Health Tech in Managing Chronic Disease
    IntroductionWearable tech – the new golden ticket for patient adherence?Wearable technology is being...
    01 May 2016 by FirstWord Pharma USD $695 More Info
    Chronic Obstructive Pulmonary Disorder (COPD): Update Bulletin [Feb 2016]
    IntroductionThis edition presents key opinion leader (KOL) views on recent developments in the chron...
    01 Feb 2016 by FirstWord Pharma USD $995 More Info
    Chronic Lymphocytic Leukaemia: Update Bulletin [Feb 2016]
    IntroductionGain new KOL insights on the latest events with the potential to shape the targeted trea...
    01 Feb 2016 by FirstWord Pharma USD $995 More Info
    Chronic Kidney Disease (Chronic Renal Failure) Global Clinical Trials Review, H2, 2015
    Chronic Kidney Disease (Chronic Renal Failure) Global Clinical Trials Review, H2, 2015SummaryGlobalD...
    30 Oct 2015 by Global Data USD $2,500 More Info
    Chronic Lymphocytic Leukaemia: KOL Insight
    IntroductionIn the last few years the emergence of new targeted therapies such as AbbVie’s/Janssen’s...
    01 Sep 2015 by FirstWord Pharma USD $7,900 More Info
    Chronic Lymphocytic Leukaemia: KOL Insight
    IntroductionChronic lymphocytic leukaemia (CLL) is the most common of the leukaemias, but until rece...
    27 May 2014 by FirstWord Pharma USD $7,900 More Info
    Chronic Obstructive Pulmonary Disorder (COPD) - KOL Insight and Consensus Outlook
    IntroductionThe prevalence of Chronic Obstructive Pulmonary Disorder (COPD) is increasing globally, ...
    20 Jan 2014 by FirstWord Pharma USD $7,495 More Info
    Physician Views: Life after Gleevec in the chronic myeloid leukaemia (CML) market?
    ScopeNovartis' Gleevec is widely credited as being one of the most important drug launches of all ti...
    01 Jun 2013 by FirstWord Pharma USD $695 More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Chronic Obstructive Pulmonary Disorder (COPD): KOL Insight [Published by FirstWord Pharma] | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...